The Value of NOTCH2NLC Gene Detection and Skin Biopsy in the Diagnosis of Neuronal Intranuclear Inclusion Disease

stjosephs-hospital

The clinical manifestations of neuronal intranuclear inclusion disease (NIID) are heterogeneous, and the premortem diagnosis is mainly based on skin biopsy findings. Abnormal GGC repeat expansions in NOTCH2NLC was recently identified in familial and sporadic NIID. The comparison of diagnostic value between abnormal GGC repeat expansions of NOTCH2NLC and skin biopsy has not been conducted yet.

In this study, skin biopsy was performed in 10 suspected adult NIID patients with clinical and imaging manifestations, and GGC repeat size in NOTCH2NLC was also screened by repeat primed-PCR and GC-rich PCR. We found that five cases had ubiquitin-immunolabelling intranuclear inclusion bodies by skin biopsy, and all of them were identified with abnormal GGC repeat expansions in NOTCH2NLC, among whom four patients showed typical linear hyperintensity at corticomedullary junction on DWI.

Five (5/10) NIID patients were diagnosed by combination of NOTCH2NLC gene detection, skin biopsy or combination of NOTCH2NLC, and typical MRI findings. The diagnostic performance of NOTCH2NLC gene detection was highly consistent with that of skin biopsy (Kappa = 1). The unexplained headache was firstly reported as a new early phenotype of NIID. These findings indicate that NOTCH2NLC gene detection is needed to be a supplement in the diagnose flow of NIID and also may be used as an alternative method to skin biopsy especially in Asian population.

 

digIS: towards detecting distant and putative novel insertion sequence elements in prokaryotic genomes

Background: The insertion sequence elements (IS elements) represent the smallest and the most abundant mobile elements in prokaryotic genomes. It has been shown that they play a significant role in genome organization and evolution. To better understand their function in the host genome, it is desirable to have an effective detection and annotation tool.

This need becomes even more crucial when considering rapid-growing genomic and metagenomic data. The existing tools for IS elements detection and annotation are usually based on comparing sequence similarity with a database of known IS families. Thus, they have limited ability to discover distant and putative novel IS elements.

Results: In this paper, we present digIS, a software tool based on profile hidden Markov models assembled from catalytic domains of transposases. It shows a very good performance in detecting known IS elements when tested on datasets with manually curated annotation. The main contribution of digIS is in its ability to detect distant and putative novel IS elements while maintaining a moderate level of false positives. In this category it outperforms existing tools, especially when tested on large datasets of archaeal and bacterial genomes.

Conclusion: We provide digIS, a software tool using a novel approach based on manually curated profile hidden Markov models, which is able to detect distant and putative novel IS elements. Although digIS can find known IS elements as well, we expect it to be used primarily by scientists interested in finding novel IS elements.

 

Gene Expression Changes in a Model Neuron Cell Line Exposed to Autoantibodies from Patients with Traumatic Brain Injury and/or Type 2 Diabetes

Traumatic brain injury and adult type 2 diabetes mellitus are each associated with the late occurrence of accelerated cognitive decline and Parkinson’s disease through unknown mechanisms. Previously, we reported increased circulating agonist autoantibodies targeting the 5-hydroxytryptamine 2A receptor in plasma from subsets of Parkinson’s disease, dementia, and diabetic patients suffering with microvascular complications.

Here, we use a model neuron, mouse neuroblastoma (N2A) cell line, to test messenger RNA expression changes following brief exposure to traumatic brain injury and/or type 2 diabetes mellitus plasma harboring agonist 5-hydroxytryptamine 2A receptor autoantibodies.

We now report involvement of the mitochondrial dysfunction pathway and Parkinson’s disease pathways in autoantibody-induced gene expression changes occurring in neuroblastoma cells. Functional gene categories upregulated significantly included cell death, cytoskeleton-microtubule function, actin polymerization or depolymerization, regulation of cell oxidative stress, mitochondrial function, immune function, protein metabolism, and vesicle function.

Gene categories significantly downregulated included microtubule function, cell adhesion, neurotransmitter release, dopamine metabolism synaptic plasticity, maintenance of neuronal differentiation, mitochondrial function, and cell signaling.

Taken together, these results suggest that agonist 5-hydroxytryptamine receptor autoantibodies (which increase in Parkinson’s disease and other forms of neurodegeneration) mediate a coordinating program of gene expression changes in a model neuron which predispose to neuro-apoptosis and are linked to human neurodegenerative diseases pathways.

stjosephs-hospital

stjosephs-hospital

Novel Alzheimer’s disease risk variants identified based on whole-genome sequencing of APOE ε4 carriers

Alzheimer’s disease (AD) is a progressive neurodegenerative disease associated with a complex genetic etiology. Besides the apolipoprotein E ε4 (APOE ε4) allele, a few dozen other genetic loci associated with AD have been identified through genome-wide association studies (GWAS) conducted mainly in individuals of European ancestry.

Recently, several GWAS performed in other ethnic groups have shown the importance of replicating studies that identify previously established risk loci and searching for novel risk loci. APOE-stratified GWAS have yielded novel AD risk loci that might be masked by, or be dependent on, APOE alleles.

We performed whole-genome sequencing (WGS) on DNA from blood samples of 331 AD patients and 169 elderly controls of Korean ethnicity who were APOE ε4 carriers. Based on WGS data, we designed a customized AD chip (cAD chip) for further analysis on an independent set of 543 AD patients and 894 elderly controls of the same ethnicity, regardless of their APOE ε4 allele status.

Combined analysis of WGS and cAD chip data revealed that SNPs rs1890078 (P = 6.64E-07) and rs12594991 (P = 2.03E-07) in SORCS1 and CHD2 genes, respectively, are novel genetic variants among APOE ε4 carriers in the Korean population.

In addition, nine possible novel variants that were rare in individuals of European ancestry but common in East Asia were identified. This study demonstrates that APOE-stratified analysis is important for understanding the genetic background of AD in different populations.

 

ECT2 Antibody

DF15648 100ul
EUR 420

ECT2 Antibody

DF15648-100ul 100ul
EUR 280

ECT2 Antibody

DF15648-200ul 200ul
EUR 350

ECT2 Antibody

CAC11271-100ug 100ug
EUR 314

ECT2 Antibody

CAC11271-50ug 50ug
EUR 199.2

ECT2 antibody

70R-5714 50 ug
EUR 467
Description: Rabbit polyclonal ECT2 antibody raised against the middle region of ECT2

ECT2 antibody

70R-5730 50 ug
EUR 467
Description: Rabbit polyclonal ECT2 antibody raised against the middle region of ECT2

ECT2 Antibody

GWB-MS591F 50ug Ask for price

ECT2 Antibody

GWB-MS592G 50ug Ask for price

ECT2 Antibody

F53947-0.05ML 0.05 ml
EUR 140.25
Description: Epithelial cell-transforming sequence 2 oncogene is a guanine nucleotide exchange factor (GEF) that catalyzes the exchange of GDP for GTP. Promotes guanine nucleotide exchange on the Rho family members of small GTPases, like RHOA, RHOC, RAC1 and CDC42. Required for signal transduction pathways involved in the regulation of cytokinesis. Component of the centralspindlin complex that serves as a microtubule-dependent and Rho-mediated signaling required for the myosin contractile ring formation during the cell cycle cytokinesis. Regulates the translocation of RHOA from the central spindle to the equatorial region. Plays a role in the control of mitotic spindle assembly; regulates the activation of CDC42 in metaphase for the process of spindle fibers attachment to kinetochores before chromosome congression. Involved in the regulation of epithelial cell polarity; participates in the formation of epithelial tight junctions in a polarity complex PARD3-PARD6-protein kinase PRKCQ-dependent manner. Plays a role in the regulation of neurite outgrowth. Inhibits phenobarbital (PB)- induced NR1I3 nuclear translocation. Stimulates the activity of RAC1 through its association with the oncogenic PARD6A-PRKCI complex in cancer cells, thereby acting to coordinately drive tumor cell proliferation and invasion. Also stimulates genotoxic stress-induced RHOB activity in breast cancer cells leading to their cell death.

ECT2 Antibody

F53947-0.2ML 0.2 ml
EUR 330.65
Description: Epithelial cell-transforming sequence 2 oncogene is a guanine nucleotide exchange factor (GEF) that catalyzes the exchange of GDP for GTP. Promotes guanine nucleotide exchange on the Rho family members of small GTPases, like RHOA, RHOC, RAC1 and CDC42. Required for signal transduction pathways involved in the regulation of cytokinesis. Component of the centralspindlin complex that serves as a microtubule-dependent and Rho-mediated signaling required for the myosin contractile ring formation during the cell cycle cytokinesis. Regulates the translocation of RHOA from the central spindle to the equatorial region. Plays a role in the control of mitotic spindle assembly; regulates the activation of CDC42 in metaphase for the process of spindle fibers attachment to kinetochores before chromosome congression. Involved in the regulation of epithelial cell polarity; participates in the formation of epithelial tight junctions in a polarity complex PARD3-PARD6-protein kinase PRKCQ-dependent manner. Plays a role in the regulation of neurite outgrowth. Inhibits phenobarbital (PB)- induced NR1I3 nuclear translocation. Stimulates the activity of RAC1 through its association with the oncogenic PARD6A-PRKCI complex in cancer cells, thereby acting to coordinately drive tumor cell proliferation and invasion. Also stimulates genotoxic stress-induced RHOB activity in breast cancer cells leading to their cell death.

ECT2 Conjugated Antibody

C43917 100ul
EUR 476.4

ECT2 Polyclonal Antibody

E-AB-53424-120uL 120uL
EUR 240
Description: Unconjugated

ECT2 Polyclonal Antibody

E-AB-53424-200uL 200uL
EUR 399
Description: Unconjugated

ECT2 Polyclonal Antibody

E-AB-53424-20uL 20uL
EUR 73
Description: Unconjugated

ECT2 Polyclonal Antibody

E-AB-53424-60uL 60uL
EUR 143
Description: Unconjugated

ECT2 Antibody, HRP conjugated

1-CSB-PA888001LB01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against ECT2. Recognizes ECT2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

ECT2 Antibody, FITC conjugated

1-CSB-PA888001LC01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against ECT2. Recognizes ECT2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

OACD03154-1ML - ECT2 Antibody

OACD03154-1ML 1ml
EUR 669

OACD03155-1ML - ECT2 Antibody

OACD03155-1ML 1ml
EUR 669

ECT2 Antibody, Biotin conjugated

1-CSB-PA888001LD01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against ECT2. Recognizes ECT2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

OACD03154-100UL - ECT2 Antibody

OACD03154-100UL 100ul
EUR 199

OACD03155-100UL - ECT2 Antibody

OACD03155-100UL 100ul
EUR 199

Rabbit Polyclonal ECT2 Antibody

TA590497 100 µg Ask for price

ECT2 Mouse Monoclonal Antibody

E10G34303 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

ECT2 Rabbit Polyclonal Antibody

E10G12612 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

ECT2 Rabbit Polyclonal Antibody

E10G05742 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Monoclonal ECT2 Antibody, Clone: 1691CT516.3.3

AMM02569G 0.1ml
EUR 580.8
Description: A Monoclonal antibody against Human ECT2. The antibodies are raised in Mouse and are from clone 1691CT516.3.3. This antibody is applicable in WB, E

OAAB11086-400UL - ECT2 Antibody - middle region

OAAB11086-400UL 400ul
EUR 389

OAGA01220-100UL - ECT2 Antibody - N-terminal region

OAGA01220-100UL 100ul
EUR 369

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

20-abx104055
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

20-abx104056
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx028279-400ul 400 ul
EUR 627.6

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx028279-80l 80 µl
EUR 343.2

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

20-abx334431
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx432637-200ul 200 ul
EUR 460.8

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx104055-100g 100 µg
EUR 750

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx104055-20g 20 µg
EUR 275

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx104055-50g 50 µg
EUR 337.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx104056-100g 100 µg
EUR 750

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx104056-20g 20 µg
EUR 275

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx104056-50g 50 µg
EUR 337.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx028279-400l 400 µl
EUR 518.75

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx432637-100g 100 µg
EUR 387.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx334431-100g 100 µg
EUR 362.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx334431-20g 20 µg
EUR 162.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody

abx334431-50g 50 µg
EUR 250

ECT2

E8ER1907-92 100ul
EUR 275
Description: Available in various conjugation types.

Monoclonal ECT2 monoclonal antibody (M01), Clone: 5D4

AMM04340G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human ECT2 monoclonal (M01). The antibodies are raised in mouse and are from clone 5D4. This antibody is applicable in WB

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (HRP)

20-abx337249
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (HRP)

abx337249-100g 100 µg
EUR 362.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (HRP)

abx337249-20g 20 µg
EUR 162.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (HRP)

abx337249-50g 50 µg
EUR 250

Ect2 (untagged) - Mouse ect2 oncogene (Ect2), transcript variant 2, (10ug)

MC222366 10 µg Ask for price

Ect2 (untagged) - Mouse ect2 oncogene (Ect2), transcript variant 1, (10ug)

MC222574 10 µg Ask for price

Ect2 (untagged) - Mouse ect2 oncogene (Ect2), transcript variant 3, (10ug)

MC220714 10 µg Ask for price

ECT2 (Center) rabbit polyclonal antibody, Aff - Purified

AP51360PU-N 400 µl Ask for price

Mouse Protein ECT2, Ect2 ELISA KIT

ELI-32217m 96 Tests
EUR 1038

Human Protein ECT2, ECT2 ELISA KIT

ELI-09348h 96 Tests
EUR 988.8

Human Protein ECT2 (ECT2) ELISA Kit

abx521509-96tests 96 tests
EUR 687.5

Mouse Protein ECT2 (ECT2) ELISA Kit

abx521510-96tests 96 tests
EUR 687.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (FITC)

20-abx337250
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (FITC)

abx337250-100g 100 µg
EUR 362.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (FITC)

abx337250-20g 20 µg
EUR 162.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (FITC)

abx337250-50g 50 µg
EUR 250

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (Biotin)

20-abx272498
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (Biotin)

20-abx337251
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (Biotin)

abx272498-1ml 1 ml
EUR 825

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (Biotin)

abx272498-200l 200 µl
EUR 362.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (Biotin)

abx337251-100g 100 µg
EUR 362.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (Biotin)

abx337251-20g 20 µg
EUR 162.5

Epithelial Cell Transforming Sequence 2 (ECT2) Antibody (Biotin)

abx337251-50g 50 µg
EUR 250

Ect2 (GFP-tagged) - Mouse ect2 oncogene (Ect2) transcript variant 1, (10ug)

MG223423 10 µg Ask for price

Ect2 (GFP-tagged) - Mouse ect2 oncogene (Ect2) transcript variant 2, (10ug)

MG224170 10 µg Ask for price

Ect2 (Myc-DDK-tagged) - Mouse ect2 oncogene (Ect2), transcript variant 1

MR223423 10 µg Ask for price

Ect2 (Myc-DDK-tagged) - Mouse ect2 oncogene (Ect2), transcript variant 3

MR211053 10 µg Ask for price

Ect2 (Myc-DDK-tagged) - Mouse ect2 oncogene (Ect2), transcript variant 2

MR224170 10 µg Ask for price

ECT2 (N-term) goat polyclonal antibody, Aff - Purified

AP16137PU-N 100 µg Ask for price

ECT2 mouse monoclonal antibody, clone OTI2D9 (formerly 2D9)

TA807408 100 µl Ask for price

ECT2 mouse monoclonal antibody, clone OTI2D9 (formerly 2D9)

TA807408S 30 µl Ask for price
Steven Washington

Related Post

stjosephs-hospital

A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaA Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Background: Induction chemotherapy (IC) adopted by concurrent chemoradiotherapy is the mainstay remedy for sufferers with locoregionally superior nasopharyngeal carcinoma. Nevertheless, some sufferers acquire little profit and expertise pointless poisonousities from IC.